| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Doris Wagner | |
| Astrid Fahrleitner-Pammer | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells | Q24321566 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease | Q31117495 | ||
| Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism | Q33726838 | ||
| The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | Q33823576 | ||
| Osteoprotegerin ligand: a regulator of immune responses and bone physiology. | Q34079327 | ||
| Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro | Q34459310 | ||
| Renal osteodystrophy and secondary hyperparathyroidism | Q34973993 | ||
| Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis | Q35638087 | ||
| Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment | Q36232629 | ||
| TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. | Q36404187 | ||
| Inflammatory bowel diseases as secondary causes of osteoporosis | Q36565219 | ||
| Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women | Q80805276 | ||
| Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women | Q80943629 | ||
| Osteoprotegerin and RANKL in alcoholic liver cirrhosis | Q81550204 | ||
| Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women | Q83214269 | ||
| The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study | Q37097170 | ||
| Osteoprotegerin--does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women? | Q38506684 | ||
| Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 | ||
| Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory. | Q39288741 | ||
| Soluble RANKL and risk of nontraumatic fracture | Q40527958 | ||
| Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis | Q43246219 | ||
| The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 | ||
| Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status | Q43666533 | ||
| Serum osteoprotegerin and renal osteodystrophy | Q43867634 | ||
| Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status | Q44325410 | ||
| Serum levels of osteoprotegerin increase with age in a healthy adult population | Q44480310 | ||
| Serum leptin in dialysis renal osteodystrophy | Q44634437 | ||
| Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. | Q44683819 | ||
| Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population | Q44793993 | ||
| Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. | Q45139267 | ||
| Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. | Q45161690 | ||
| Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males | Q45215925 | ||
| The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women | Q45265577 | ||
| High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. | Q45928348 | ||
| Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis. | Q45941445 | ||
| The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure. | Q45994331 | ||
| The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study | Q46081382 | ||
| Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. | Q46535196 | ||
| Skeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol. | Q46599165 | ||
| Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women | Q46729843 | ||
| Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial | Q46753882 | ||
| The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa | Q46902918 | ||
| Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients | Q46910500 | ||
| Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). | Q46956288 | ||
| Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status | Q47852837 | ||
| Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients | Q50086342 | ||
| Calcium supply, bone mineral density and genetically defined lactose maldigestion in a cohort of elderly men. | Q51765339 | ||
| Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. | Q51796802 | ||
| Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. | Q53231896 | ||
| The RANKL/OPG system and bone mineral density in patients with chronic liver disease. | Q53658379 | ||
| Immunology and aging | Q58143512 | ||
| Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins | Q59056838 | ||
| Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation | Q72991541 | ||
| High serum osteoprotegerin and low RANKL in primary biliary cirrhosis | Q73187923 | ||
| Serum measurement of osteoprotegerin--clinical relevance and potential applications | Q77225522 | ||
| Bone density and markers of bone remodeling in type 1 male diabetic patients | Q79366074 | ||
| Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major | Q79449674 | ||
| Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women | Q79759881 | ||
| Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation | Q79848042 | ||
| Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease | Q80085809 | ||
| Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women | Q80166841 | ||
| Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover | Q80413583 | ||
| Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide | Q80771538 | ||
| P433 | issue | 17-18 | |
| P304 | page(s) | 452-457 | |
| P577 | publication date | 2010-08-16 | |
| P1433 | published in | Wiener Medizinische Wochenschrift | Q2568998 |
| P1476 | title | Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help? | |
| P478 | volume | 160 |
| Q36801757 | A Special Ingredient (VtR) Containing Oligostilbenes Isolated from Vitis thunbergii Prevents Bone Loss in Ovariectomized Mice: In Vitro and In Vivo Study |
| Q47252258 | A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma |
| Q90207937 | Association between Inflammatory Potential of Diet and Bone-Mineral Density in Korean Postmenopausal Women: Data from Fourth and Fifth Korea National Health and Nutrition Examination Surveys |
| Q34974286 | Biochemical markers of bone metabolism in children with cow's milk allergy. |
| Q58215669 | Commentary: A single biomarker in a complex metabolic pathway |
| Q28730855 | Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial |
| Q47172251 | Diet, weight, cytokines and bone health in postmenopausal women |
| Q90419106 | Differential Modulation of Cancellous and Cortical Distal Femur by Fructose and Natural Mineral-Rich Water Consumption in Ovariectomized Female Sprague Dawley Rats |
| Q38625798 | Effects of short-term dry immersion on bone remodeling markers, insulin and adipokines. |
| Q36410243 | Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients? |
| Q37320875 | OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study |
| Q86521401 | Osteoprotegerin and fractures in men and women with chronic kidney disease |
| Q37149062 | Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene |
| Q37322445 | Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor- κ B Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus |
| Q36842216 | Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study |
| Q28245828 | Relationship between serum RANKL and RANKL in bone |
| Q37344527 | Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection |
| Q92967953 | The impact of nonosteogenic factors on the expression of osteoprotegerin and RANKL during human fracture healing |
| Q37922640 | The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review |
| Q46567942 | Total oxidant status and bone resorption biomarkers in serum and gingival crevicular fluid of patients with periodontitis |
Search more.